UBS raises BrightSpring Health stock price target to $92 on growth outlook
UBS increased its price target for BrightSpring Health Services (BTSG) to $92 from $85, citing growth prospects in its Specialty Pharmacy and Infusion businesses. The stock has surged 102% over the past year. The company reported Q3 2026 earnings of $0.54 per share, beating estimates, and raised its 2026 revenue guidance to $15.9B-$16.125B. Goldman Sachs also raised its target to $90, highlighting strong growth.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest a near‑term rally, but investors should monitor execution risk in specialty pharmacy growth.
Market read
Strong earnings and upgraded targets could drive BTSG higher in the short term.
What to watch
Potential regulatory scrutiny of specialty pharmacy pricing could temper upside.
Background
BrightSpring Health Services reported Q3 2026 results that beat expectations, prompting UBS and Goldman Sachs to raise price targets.
Ticker impact
UBS raised its price target on BrightSpring Health Services to $92 and reported Q3 2026 earnings beat, prompting a bullish outlook.
upward pressure as the market prices in higher earnings expectations and raised price targets
Both UBS and Goldman Sachs increased price targets after the company posted earnings that far exceeded expectations and raised guidance.
Market effects
Positive earnings and guidance may lift other specialty pharmacy and home health providers.
U.S. healthcare sector could see modest gains.
Limited to U.S. listed health services firms.
Counterpoint
The raised guidance may be overly optimistic given potential reimbursement pressures.
Key entities
- companyBrightSpring Health Services
U.S. health services provider listed on NASDAQ.
- analystUBS
Investment bank that raised the price target to $92.
- analystGoldman Sachs
Investment bank that raised the price target to $90.
